抑制磷酸二酯酶4通过干扰M2巨噬细胞释放白介素-6减轻皮肤纤维化
该研究在博来霉素诱导皮肤纤维化、拓扑异构酶I小鼠模型及硬化性慢性移植物抗宿主病模型中评估PDE4抑制的疾病修饰作用,发现罗利普兰和阿普司特具有强效抗纤维化效应,机制为减少M2巨噬细胞分化及促纤维化细胞因子释放,其中白介素-6起核心作用。
要点
- PDE4抑制剂在多种SSc临床前模型中显示强效抗纤维化作用。
- 成纤维细胞并非PDE4阻断抗纤维化效应的直接靶点。
- PDE4抑制减少M2巨噬细胞分化及促纤维化细胞因子释放,白介素-6居核心地位。
核心结论
- PDE4抑制减少炎症细胞活性及M2巨噬细胞释放促纤维化细胞因子,进而降低成纤维细胞活化和胶原释放。
- PDE4抑制剂可能被进一步开发为SSc患者的潜在抗纤维化疗法,尤其炎症驱动纤维化患者可能获益。
研究设计与样本
- 在博来霉素诱导皮肤纤维化的预防模型和治疗模型、拓扑异构酶I小鼠模型及硬化性慢性移植物抗宿主病模型中研究PDE4抑制的效应。
- 在来自健康个体和弥漫性皮肤型SSc患者的成纤维细胞和巨噬细胞中,于阻断PDE4后检测纤维化相关介质。
主要发现
- 罗利普兰和阿普司特特异性抑制PDE4,在博来霉素诱导皮肤纤维化模型、拓扑异构酶I小鼠模型及小鼠硬化性慢性移植物抗宿主病中具有强效抗纤维化效应。
- PDE4阻断后病灶皮肤白细胞浸润减少,提示免疫介导机制。
- PDE4抑制减少M2巨噬细胞分化及多种促纤维化细胞因子释放,导致成纤维细胞活化和胶原释放减少。
- 在这些促纤维化介质中,白介素-6似乎起核心作用。
临床怎么用
- 阿普司特已获批用于治疗银屑病和银屑病关节炎,PDE4抑制剂可能进一步开发为SSc的抗纤维化疗法。
- 研究结果提示尤其炎症驱动纤维化的患者可能从PDE4阻断中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the disease-modifying effects of phosphodiesterase 4 (PDE4) inhibition in preclinical models of systemic sclerosis (SSc). METHODS: We studied the effects of PDE4 inhibition in a prevention and a treatment model of bleomycin-induced skin fibrosis, in the topoisomerase mouse model as well as in a model of sclerodermatous chronic graft-versus-host disease. To better understand the mode of action of PDE4 blockade in preclinical models of SSc, we investigated fibrosis-relevant mediators in fibroblasts and macrophages from healthy individuals and patients suffering from diffuse-cutaneous SSc on blockade of PDE4. RESULTS: Specific inhibition of PDE4 by rolipram and apremilast had potent antifibrotic effects in bleomycin-induced skin fibrosis models, in the topoisomerase I mouse model and in murine sclerodermatous chronic graft-versus-host disease. Fibroblasts were not the direct targets of the antifibrotic effects of PDE4 blockade. Reduced leucocyte infiltration in lesional skin on PDE4 blockade suggested an immune-mediated mechanism. Further analysis revealed that PDE4 inhibition decreased the differentiation of M2 macrophages and the release of several profibrotic cytokines, resulting in reduced fibroblast activation and collagen release. Within these profibrotic mediators, interleukin-6 appeared to play a central role. CONCLUSIONS: PDE4 inhibition reduces inflammatory cell activity and the release of profibrotic cytokines from M2 macrophages, leading to decreased fibroblast activation and collagen release. Importantly, apremilast is already approved for the treatment of psoriasis and psoriatic arthritis. Therefore, PDE4 inhibitors might be further developed as potential antifibrotic therapies for patients with SSc. Our findings suggest that particularly patients with inflammation-driven fibrosis might benefit from PDE4 blockade.
引用
- Maier C, Ramming A, Bergmann C, et al. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis. 2017. PMID: 28209630. doi:10.1136/annrheumdis-2016-210189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。